Nevirapine Milpharm (Nevirapine)

Nevirapine belongs to the non‑nucleoside reverse transcriptase inhibitor class. It binds to a specific hydrophobic pocket on the HIV‑1 reverse transcriptase enzyme, causing a conformational change that blocks the enzyme’s activity. This prevents the conversion of viral RNA into DNA, halting viral replication.

The exact dosing regimen for Nevirapine is determined by the prescribing clinician based on the patient’s clinical status, weight, and co‑medications. Standard practice involves an initial lead‑in dose followed by a maintenance dose, but the prescriber sets the final schedule.

Nevirapine’s pregnancy category is listed as unknown, and safety data are limited. Use during pregnancy or lactation should be considered only when the potential benefit to the mother outweighs possible risks to the fetus or infant, and it should be prescribed under specialist supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nevirapine is an NNRTI, similar to efavirenz and delavirdine, but differs in its metabolic profile and side‑effect spectrum. Compared with protease inhibitors, NNRTIs generally have fewer drug‑food interactions but may carry a higher risk of skin rash and hepatic toxicity, requiring individualized selection.

Nevirapine Milpharm tablets should be stored at temperatures below 25 °C, in the original container, protected from moisture and direct sunlight. Keep the product out of reach of children and avoid exposing it to excessive heat or humidity.

Nevirapine is taken orally, usually with food or a light snack to reduce gastrointestinal discomfort. The tablets are swallowed whole with water and should be taken exactly as prescribed, without crushing or splitting unless instructed by a healthcare professional.

The most critical adverse events include severe skin reactions such as Stevens‑Johnson syndrome, life‑threatening hepatic failure, and hypersensitivity reactions that may involve fever, rash, and organ involvement. Prompt medical evaluation is essential if any of these symptoms appear.

Nevirapine is contraindicated in individuals with a known hypersensitivity to the drug or any NNRTI, patients with severe pre‑existing liver disease, and those who have previously experienced severe rash or hepatic reactions to nevirapine. Caution is also advised for patients with active hepatitis B or C.